Taking peoplePhase 2
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease
Key facts
- Phase
- Phase 2
This trial has no sites in United States.
It has sites in 11 countries. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- Immunovant Sciences GmbH
- Trial code
- EU 2025-524001-33-00
- Record updated
- 10 August 2026
- Original description
To evaluate the efficacy of IMVT-1402 as assessed by maintenance of euthyroidism, off ATD, and off IMVT-1402 for 52 weeks in Group A ParticipantsRead full original descriptionShow less
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
To evaluate the efficacy of IMVT-1402 as assessed by maintenance of euthyroidism, off ATD, and off IMVT-1402 for 52 weeks in Group A Participants
Inclusion: Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503.
Exclusion: Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study.